TRV GP II’s Blueprint Medicines BPMC Stock Holding History

TRV GP II’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-878,875	Closed	-$70.4M	–	3
2019 Q1	$70.4M	Hold	878,875	–	–	45.87%	1
2018 Q4	$47.4M	Hold	878,875	–	–	47.08%	1
2018 Q3	$68.6M	Hold	878,875	–	–	40.27%	1
2018 Q2	$55.8M	Sell	878,875 -1,574,878	-64%	-$125M	31.63%	2
2018 Q1	$225M	Hold	2,453,753	–	–	42.17%	2
2017 Q4	$185M	Buy	+2,453,753	New	+$173M	33.32%	1

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

TRV GP II's BPMC Position: Q2 2019 in Review

TRV GP II sold out of Blueprint Medicines (BPMC) in Q2 2019, closing a stake of 878,875 shares — an estimated $70.4M sold.

TRV GP II first reported a position in BPMC in Q4 2017 and held it in 6 quarters. The position peaked at $225M in Q1 2018. 220 funds tracked by Wall St. Rank hold BPMC as of Q2 2019.

TRV GP II reported no remaining Blueprint Medicines position as of Q2 2019 after selling out during the quarter.
TRV GP II sold 878,875 Blueprint Medicines shares in Q2 2019, an estimated $70.4M.
TRV GP II first reported a position in Blueprint Medicines in Q4 2017 and held it in 6 quarters.
TRV GP II's Blueprint Medicines position peaked at $225M in Q1 2018.
220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2019.

Based on TRV GP II's 13F filing for Q2 2019, filed 6 Aug 2019.